Biosimilars: FDA’s Four-Tiered Assessment Draws Industry Scrutiny
This article was originally published in PharmAsia News
Executive Summary
PhRMA asks FDA to remove the categorization of a product as not similar, similar, highly similar, or similar with fingerprint-like similarity.
You may also be interested in...
Biosimilar Draft Guidance Outlines Three-Arm Bridging Studies For Non-U.S. Products
Clinical pharmacology data could help biosimilar sponsors pursue a more global development plan.
FDA Biosimilars Guidances Address Immunogenicity Studies, European Bridge Data, Analytics
The agency’s first three draft guidances on biosimilar product development describe how to characterize biosimilar and reference products and extrapolate data on one condition of use to another. FDA says interchangeability is difficult to determine now and will require a switching study.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.